lilly tirzepatide vials Zepbound Shortage: Patients Push Eli to Release More Obesity Drug Supply Lilly Releases Zepbound (Tirzepatide) Single-dose

Do not skip this

The GIP receptor agonism may complement these effects, potentially contributing to the medication's pronounced weight loss effects observed in clinical trials

Refrigeration is required

Certain compounded products may have significant risks, such as dosing errors and contamination

Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)